BC Innovations | Jun 19, 2014
Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Poisoning Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1); PHD2 (EGLN1; HIF-PH2); PHD3 (EGLN3; HIF-PH3) Mouse studies suggest pan-PHD inhibitors could help prevent damage to...
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in China,...
BC Week In Review | Feb 9, 2009
Clinical News

ASP1517: Phase II resumed

FibroGen resumed enrollment in a single-blind, placebo-controlled, dose-escalation Phase II trial evaluating oral ASP1517 in 130 non-dialysis patients. The study was placed on hold in 2007 after a patient receiving another oral HIF-PH inhibitor, FG-2216...
BC Innovations | Jan 15, 2009
Targets & Mechanisms

Arresting infant retinopathy

Researchers at the Cleveland Clinic have found that activating hypoxia-inducible factor can prevent the progression of retinopathy in premature infants, which results in blindness if left unchecked. The findings, reported in the Proceedings of the...
BC Week In Review | Apr 7, 2008
Clinical News

FG-2216: Phase II data

In a U.S. Phase II trial, twice-weekly oral doses of 375, 625 and 1,250 mg of FG-2216 led to Hb responses, defined as increases of 1 g/dL, in 13 (50%), 31 (60%) and 38 (76%)...
BC Week In Review | Apr 7, 2008
Clinical News

FG-4592: Phase II resumed

FDA lifted a clinical hold on FG-4592 and another oral HIF-PH inhibitor, FG-2216 (YM 311), that are in Phase II testing to treat anemia in CKD patients. Last May, FDA placed a clinical hold on...
BC Innovations | Mar 6, 2008
Targets & Mechanisms

Anemia's Gas6 pedal

A relatively large percentage of anemic patients who receive therapy with erythropoiesis-stimulating agents are either hyporesponsive or resistant to erythropoietin. Researchers at the University Hospital Center and University of Lausanne may have found a new...
BC Week In Review | Nov 12, 2007
Clinical News

FG-2216: Phase I data

In a German Phase I trial in hemodialysis patients and healthy volunteers, single doses of FG-2216 increased median EPO levels to 240.6 from 7.8 mIU/mL in 6 patients with kidneys, and to 57.8 from 4.4...
BioCentury | Jul 16, 2007
Strategy

Front loaded

Front loaded Year Licensor Licensee Upfront/ Equity (A) Deal terms 2007 Intercell Novartis $365 €120M ($162.4M) up front plus €150M ($203M) equity investment; rights to IC31 adjuvant for influenza vaccines and opt-in rights to Intercell's...
BC Week In Review | May 14, 2007
Clinical News

FG-2216: Phase II data

Astellas said a patient receiving FG-2216 died of fulminant hepatitis in a U.S. Phase II trial to treat anemia. The trial, which is being run by FibroGen, is ongoing and the case has been reported...
Items per page:
1 - 10 of 22